The global gouty arthritis market is predicted to develop because to the high prevalence of gouty arthritis
Gouty arthritis is characterised by severe joint pain caused by uric acid crystal deposition. Gouty arthritis is characterised by redness and swelling of the joints, as well as excruciating pain. Medication can be used to aid with the problem. Uric acid is deposited as a result of either excessive ingestion or the body's inability to digest it, causing inflammation in joints such as the ankles, toes, and wrists. Untreated gouty arthritis can harm joints and kidneys by accumulating too much uric acid crystals, which can cause kidney stones and kidney failure. It's usually associated with other metabolic disorders or conditions like hypertension, obesity, or diabetes.
High prevalence of associated chronic diseases to provide growth to gouty arthritis market
Gout is frequently coupled with other comorbidities, such as hypertension. According to a research published in the Journal of Rheumatology in 2014, approximately 75% of gouty arthritis patients have hypertension. As a result, patients with chronic diseases are more likely to develop gouty arthritis. The global gouty arthritis market is predicted to develop because to the high prevalence of gouty arthritis. According to a study published in the British Medical Journal in 2017, the global prevalence of gouty arthritis ranges from 1% to 10%. Furthermore, variables like as rising global intake of high-protein foods, which has been associated to gouty arthritis, and rising public awareness of the need of early treatment of disease are the factors boosting growth of gouty arthritis market.
Gouty arthritis market growth is hampered by a lack of understanding among the medical community about effective treatment of the ailment, particularly in emerging markets. For example, there is disagreement over whether or not to employ urate lowering medications in acute gouty arthritis. Urate lowering agents lower blood urate levels to aid in the breakdown of urate crystals, which is accomplished either by reducing serum uric acid synthesis or by increasing its excretion. Furthermore, the high costs associated with chronic gouty arthritis treatment therapy limit the expansion of the gouty arthritis market.
North America holds dominant position in gouty arthritis market
Coherent Market Insights has segmented the gouty arthritis market into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Because of the high frequency of gouty arthritis in the United States, North America is likely to dominate the gouty arthritis market. From 2013 to 2015, an estimated 54.4 million patients suffered from some kind of arthritis, with gouty arthritis accounting for a major portion of these cases, according to the Centers for Disease Control and Prevention (CDC). According to clinical recommendations for gout published in Annals of Internal Medicine in 2017, roughly 3.9 percent of persons in the United States over the age of 20 have experienced gout at least once in their lives. Furthermore, due to the high frequency of gouty arthritis in individuals over 40 years of age, the market is growing due to an increasing elderly population. The development of new and effective medicines to treat gouty arthritis is projected to drive the gouty arthritis market forward. For example, in 2015, Astra Zeneca received FDA approval for the novel molecule lesinurad (Zurampic). Lesinurad is a urate transport inhibitor that works by inhibiting URAT1, a protein involved in uric acid reabsorption in the kidneys. When combined with a xanthine oxidase inhibitor, it can help patients attain their goal serum uric acid level. As stated by WHO factsheet 2012, the Asia Pacific region is gaining significant traction in this market, owing to an increasing number of patients suffering from chronic diseases such as diabetes, cardiovascular disease, or chronic kidney disease, which are rising incrementally. This is due to established fact that around 75% of hypertensive patients have gouty arthritis, according to a study published in Journal of Rheumatology in 2014.
Comments
Post a Comment